Today, an advisory panel met to discuss and vote on whether or not to recommend if the FDA should pull diabetes drug Avandia from the market over a possible link to increased risk of heart attacks. In the end, the voting leaves no definite direction for how the FDA will ultimately come down on the issue. [More]
